Roche’s alleged exclusion of biosimilars sent to Belgian authority’s board
Roche Group has seen Belgian antitrust enforcers escalate a probe into allegations it hindered competition from biosimilar challengers to its own cancer treatments, according to a senior official. Anne-Charlotte Prévot, a prosecutor...To view the full article, register now.
Already a subscriber? Click here to view full article